Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

We'll know more about the company's medium-term prospects by the end of the year.

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

JMIR Publications today featured two new stories in its News and Perspectives section, highlighting a shift toward proactive, ...

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.